Pharmacovigilance obligations present significant challenges for biotechs. Small companies face the same rigor as large pharma – and it does not help that there is divergence between the requirements of the FDA, the EU and its member states. Here, seasoned pharmacovigilance experts and non-executive advisors to Arriello, Eric Caugant in Paris and Judi Sills in New Jersey, chart the main differences between US and EU requirements and suggest a practical path to compliance.
The reality is dawning for the thriving biotech community that their pharmacovigilance (PV) obligations are equivalent to those of pharma companies several times their size.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
For young, ambitious, product-oriented companies, such demands could be a barrier to market success – unless they devise optimum strategies for fulfilling the differing safety demands of respective regulators.
Companies with ambitions for Europe and the US tend to favour filing in the US first. On top of the US market’s vast size, it benefits from being a single country governed by one main agency – the US Food and Drug Administration (FDA). In Europe, marketing authorisation can take much longer because beyond the central European Medicines Agency (EMA) each EU member state has its own unique requirements to navigate.
Taking the US and EU as key territories, the diverse PV requirements highlighted below give a flavour of just what is involved and where biotechs are likely to need help.
Pre-marketing PV commitments
Although in the pre-marketing stage of development, most PV requirements are harmonised across the European and US markets, there are some small, noteworthy variations – for instance the FDA’s particular requirements around causality assessment, affecting what is submitted in the two regions.
Even at a central level, EMA submissions have a different look and format to US dossiers, so require different handling. For instance, the Summary of Product Characteristics (SmPC) and labelling in relation to side effects are not presented in the same way in Europe.
Differences exist too between the risk management approaches – the FDA’s Risk Evaluation and Mitigation Strategies (REMS) versus EMA’s Risk Management Plan (RMP) – and one cannot be substituted for the other. Failure to factor in these differences could present an issue at the time of filing. In addition, national EU-specific requirements may be requested in certain countries, on top of the RMP EU requirements, even for centralised procedures.
To successfully and efficiently navigate the differences between regions, biotechs must set out a clear strategy and timeline for how they will file to their target markets – and plan for multiple markets concurrently (it could take a long time to prepare for EMA’s diverse requirements, and those of each EU country beyond that, plus the UK which now sits outside of the EU/EMA).
It is not just European information and formatting requirements that differ and are more involved than in the US. Standard operating procedures (SOPs) or process requirements can be more complex in Europe too. (Although, during the pandemic, ‘crisis mode’ enabled emergency acceleration of these processes to expedite the marketing authorisation of vital products such as the US-originating Moderna vaccine for use in European markets, this approval was ‘conditional’ and such measures are temporary and cannot be expected going forward.)
Post-marketing PV requirements
The post-marketing regulatory environment is highly regulated and inspection driven. It is here that biotechs are likely to find the greatest challenges in managing their PV obligations and where the differences between US and European requirements are starker.
Europe overhauled its post-marketing PV requirements a couple of decades ago, making these very clear and prescriptive. For post-marketing safety studies, for instance, it has broken down the requirements for interventional versus non-interventional studies and what needs to be reported or left out for each. In the US, equivalent post-marketing safety requirements are much older and leave much to interpretation, so companies tend to tread a more cautious path.
Where Europe is content with a final study report, in the US companies still file expedited single case reports (in the EU, expedited reporting is required for Individual Case Safety Report (ICSRs) for post-marketing safety studies). If studies are used to support a product claim and the right data has not been collected in the right way for the given market, this could pose problems. So, the different requirements must be well understood and designed into post-marketing and market research studies.
Filling capability gaps
Although biotechs may lead the way with product expertise, this is not typically matched in understanding and expertise in PV requirements and process rigor. To mitigate safety compliance related risk, they need to establish both the right knowledge and experience, plus skills in writing SOPs and setting up PV systems which, in Europe, must be in place from the time of MA filing.
Relying on a third-party safety services provider to take on this burden without in-house oversight is not recommended – not least because the marketing authorisation holder (MAH) retains ultimate responsibility for PV compliance. As a result, irrespective of the biotech’s size and scale, it will need to bring in someone experienced who understands PV and can keep a check on vendor quality.
In Europe, a nominated Qualified Person responsible for PV (QPPV) is personally responsible for the safety of the human pharmaceutical products marketed by that company in the EU. There will need to be a designated person inside each region, too: so, a US company with European MA must have a named QPPV based in Europe; and potentially also at a country-level (in France and Spain this is a regulatory requirement).
Determining accountability
Where biotechs have entered into distribution relationships with other MAHs, there will be additional considerations, eg, who will co-ordinate and be responsible for the PV requirements in a given market and how this will be written in any contracts. The MAH in the local country is always ultimately responsible for meeting PV requirements in that country. There is also the decision of who will be the global PV database holder, this is usually the company that developed the product and secured approval.
Relying on a third-party safety services provider to take on this burden without in-house oversight is not recommended”
Meanwhile, the increase in combination treatments involving drugs and devices could trigger new rules clarifying how responsibility for adverse drug reactions is apportioned, another situation that needs to be tracked. Establishing an appropriate PV budget will be essential for any biotech navigating all this international complexity – and taking a strategic approach to filling gaps in capability.
PV capabilities should not stand still either. Biotechs will need to keep pace with both changes to regulatory requirements across all markets globally and evolving channels and technologies when tracking safety signals. They have an obligation to monitor and filter web or social media forums for potentially important real-world safety information, where digital media is company-sponsored.
About the authors
Dr Judith M. Sills and Dr Eric Caugant, both pharma industry and pharmacovigilance veterans, are non-executive directors and advisors to Arriello, a leading provider of risk management and compliance services to the Life Sciences industry.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.